Education
About Us
Working with TipRanks
Follow Us
RVL Pharmaceuticals (RVLPQ)
OTHER OTC:RVLPQ
RVLPQ Stock Chart & Stats
<$0.01
>-$0.01(-99.00%)
At close: 4:00 PM EST
<$0.01
>-$0.01(-99.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume2.10K
Average Volume (3M)N/A
Market Cap
$111.00
Enterprise ValueN/A
Total Cash (Recent Filing)$19.16M
Total Debt (Recent Filing)$58.15M
Price to Earnings (P/E)―
Beta244.64
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding111,406,044
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.97
Price to Sales (P/S)2.02
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RVL Pharmaceuticals News
RVLPQ FAQ
What was RVL Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is RVL Pharmaceuticals’s market cap?
RVL Pharmaceuticals’s market cap is $111.00.
When is RVL Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were RVL Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is RVL Pharmaceuticals overvalued?
According to Wall Street analysts RVL Pharmaceuticals’s price is currently Overvalued.
Does RVL Pharmaceuticals pay dividends?
RVL Pharmaceuticals does not currently pay dividends.
What is RVL Pharmaceuticals’s EPS estimate?
RVL Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RVL Pharmaceuticals have?
RVL Pharmaceuticals has 111,406,044 shares outstanding.
What happened to RVL Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RVL Pharmaceuticals?
Currently, no hedge funds are holding shares in RVLPQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RVL Pharmaceuticals
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
PainReform
―
Dermata Therapeutics
―
Ownership Overview
―
Insiders
―
Mutual Funds
13.86% Other Institutional Investors
86.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---